Compared, cited
Ozempic vs Wegovy
Ozempic and Wegovy are the same medicine - semaglutide - from the same maker. The difference is the approved use and the dose, not the molecule. Here is what actually separates them.
By An NayalLast reviewed 5 sources
Pepteca is a cited peptide reference. We do not sell peptides and take no affiliate money. Every figure below traces to a source on the linked library pages, with a clear line between what is clinically studied and what is community-reported.
| At a glance | Ozempic | Wegovy |
|---|---|---|
| Molecule | Semaglutide | Semaglutide (identical) |
| FDA-approved for | Type 2 diabetes; heart and kidney risk | Weight management; heart risk; MASH (2025) |
| Max dose | 2 mg weekly | 2.4 mg weekly standard (7.2 mg optional HD dose, FDA-approved March 2026) |
| Half-life | ~7 days | ~7 days (same) |
| Weight loss data | Not its approved use (off-label) | -14.9% average (STEP 1, 68 wk) |
| Form | Prefilled injector pen | Prefilled injector pen |
Same molecule, different label
Both Ozempic and Wegovy are semaglutide, made by Novo Nordisk. Ozempic is FDA-approved for type 2 diabetes, plus reducing cardiovascular and kidney risk in specific groups. Wegovy is FDA-approved for chronic weight management, plus cardiovascular risk reduction, and as of August 2025 for noncirrhotic MASH with moderate to advanced liver fibrosis. Using Ozempic purely for weight loss is off-label.
Dose and access
Wegovy titrates to a slightly higher standard maximum (2.4 mg weekly) than Ozempic (2 mg), and the FDA approved an optional 7.2 mg 'Wegovy HD' step in March 2026 for patients who have tolerated 2.4 mg and need more weight reduction. Because the approved indications differ, insurance coverage often differs too - a diabetes plan may cover Ozempic while an obesity indication routes to Wegovy. The molecule and its cautions are the same.
Who fits which
Ozempic
Prescribed for type 2 diabetes and associated cardiovascular or kidney risk.
Wegovy
Prescribed for chronic weight management (and now MASH). The version studied and approved for weight loss.
The cited card
Ozempic
semaglutide, for diabetes
Questions people ask
Are Ozempic and Wegovy the same thing?
They are the same medicine, semaglutide, from the same maker. They differ in approved use (diabetes vs weight management) and maximum dose (2 mg vs a 2.4 mg standard maintenance, with an optional 7.2 mg 'Wegovy HD' step since March 2026), not in the molecule.
Can you use Ozempic for weight loss?
Ozempic is not FDA-approved for weight loss, so that use is off-label. Wegovy is the semaglutide brand approved and dosed for chronic weight management.
Sources
- [1]Ozempic (semaglutide) FDA label, DailyMedOzempic approved for type 2 diabetes and cardiovascular/kidney risk reduction; not weight loss.
- [2]Wegovy (semaglutide) FDA label, DailyMedWegovy approved for chronic weight management and cardiovascular risk reduction.
- [3]Wegovy approved by FDA for noncirrhotic MASH with moderate to advanced liver fibrosis, Novo Nordisk, August 2025Wegovy's 2025 accelerated FDA approval for noncirrhotic MASH with moderate to advanced fibrosis (the DailyMed label snapshot predates this indication).
- [4]Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJM 2021Semaglutide 2.4 mg: -14.9% mean weight change vs -2.4% placebo at 68 weeks.
- [5]FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide (Wegovy HD, 7.2 mg), March 19, 2026FDA approval of an optional 7.2 mg Wegovy maintenance dose for patients who have tolerated 2.4 mg and need additional weight reduction.
Full cited data for each compound is on its library page, linked above. Weight-loss figures are trial averages; individual results vary.
Related comparisons